- Home
- BBUC vs NMRA Comparison
BBUC vs NMRA Comparison
Compare BBUC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBUC
- NMRA
- Stock Information
- Founded
- BBUC 2022
- NMRA 2019
- Country
- BBUC United States
- NMRA United States
- Employees
- BBUC N/A
- NMRA N/A
- Industry
- BBUC
- NMRA
- Sector
- BBUC
- NMRA
- Exchange
- BBUC Nasdaq
- NMRA Nasdaq
- Market Cap
- BBUC 1.9B
- NMRA 1.7B
- IPO Year
- BBUC N/A
- NMRA 2023
- Fundamental
- Price
- BBUC $23.92
- NMRA $2.48
- Analyst Decision
- BBUC
- NMRA Strong Buy
- Analyst Count
- BBUC 0
- NMRA 6
- Target Price
- BBUC N/A
- NMRA $20.67
- AVG Volume (30 Days)
- BBUC 48.3K
- NMRA 4.4M
- Earning Date
- BBUC 01-01-0001
- NMRA 11-12-2024
- Dividend Yield
- BBUC 0.78%
- NMRA N/A
- EPS Growth
- BBUC N/A
- NMRA N/A
- EPS
- BBUC N/A
- NMRA N/A
- Revenue
- BBUC $7,945,000,000.00
- NMRA N/A
- Revenue This Year
- BBUC N/A
- NMRA N/A
- Revenue Next Year
- BBUC N/A
- NMRA N/A
- P/E Ratio
- BBUC N/A
- NMRA N/A
- Revenue Growth
- BBUC 56.83
- NMRA N/A
- 52 Week Low
- BBUC $18.21
- NMRA $1.83
- 52 Week High
- BBUC $28.29
- NMRA $21.00
- Technical
- Relative Strength Index (RSI)
- BBUC 42.48
- NMRA 19.40
- Support Level
- BBUC $22.81
- NMRA $1.83
- Resistance Level
- BBUC $24.42
- NMRA $11.57
- Average True Range (ATR)
- BBUC 0.90
- NMRA 0.75
- MACD
- BBUC 0.00
- NMRA -0.94
- Stochastic Oscillator
- BBUC 35.13
- NMRA 6.67
About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a global basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.